Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself

CM McCrudden; MG O'Rourke; KE Cherry; HF Yuen; D O'Rourke; M Babur; BA Telfer; HD Thomas; P Keane; T Nambirajan; C Hagan; JM O'Sullivan; C Shaw; KJ Williams; NJ Curtin; DG Hirst; T Robson

doi:10.1371/journal.pone.0118187

Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself

CM McCrudden, MG O'Rourke, KE Cherry, HF Yuen, D O'Rourke, M Babur, BA Telfer, HD Thomas, P Keane, T Nambirajan, C Hagan, JM O'Sullivan, C Shaw, KJ Williams, NJ Curtin, DG Hirst, T Robson

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	e0118187
Pages (from-to)	e0118187
Journal	P L o S One
Volume	10
Issue number	2
DOIs	https://doi.org/10.1371/journal.pone.0118187
Publication status	Published - 17 Feb 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pone.0118187

Cite this

McCrudden, CM., O'Rourke, MG., Cherry, KE., Yuen, HF., O'Rourke, D., Babur, M., Telfer, BA., Thomas, HD., Keane, P., Nambirajan, T., Hagan, C., O'Sullivan, JM., Shaw, C., Williams, KJ., Curtin, NJ., Hirst, DG., & Robson, T. (2015). Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself. P L o S One, 10(2), e0118187. Article e0118187. https://doi.org/10.1371/journal.pone.0118187

@article{3a508fb3acaa448cbfad71ea09834be3,

title = "Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself",

author = "CM McCrudden and MG O'Rourke and KE Cherry and HF Yuen and D O'Rourke and M Babur and BA Telfer and HD Thomas and P Keane and T Nambirajan and C Hagan and JM O'Sullivan and C Shaw and KJ Williams and NJ Curtin and DG Hirst and T Robson",

year = "2015",

month = feb,

day = "17",

doi = "10.1371/journal.pone.0118187",

language = "English",

volume = "10",

pages = "e0118187",

journal = "P L o S One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "2",

}

McCrudden, CM, O'Rourke, MG, Cherry, KE, Yuen, HF, O'Rourke, D, Babur, M, Telfer, BA, Thomas, HD, Keane, P, Nambirajan, T, Hagan, C, O'Sullivan, JM, Shaw, C, Williams, KJ, Curtin, NJ, Hirst, DG & Robson, T 2015, 'Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself', P L o S One, vol. 10, no. 2, e0118187, pp. e0118187. https://doi.org/10.1371/journal.pone.0118187

TY - JOUR

T1 - Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself

AU - McCrudden, CM

AU - O'Rourke, MG

AU - Cherry, KE

AU - Yuen, HF

AU - O'Rourke, D

AU - Babur, M

AU - Telfer, BA

AU - Thomas, HD

AU - Keane, P

AU - Nambirajan, T

AU - Hagan, C

AU - O'Sullivan, JM

AU - Shaw, C

AU - Williams, KJ

AU - Curtin, NJ

AU - Hirst, DG

AU - Robson, T

PY - 2015/2/17

Y1 - 2015/2/17

U2 - 10.1371/journal.pone.0118187

DO - 10.1371/journal.pone.0118187

M3 - Article

SN - 1932-6203

VL - 10

SP - e0118187

JO - P L o S One

JF - P L o S One

IS - 2

M1 - e0118187

ER -